胰腺癌术后延长静脉血栓栓塞药物预防:皮下注射能否改变结局?
单中心回顾性分析1667例因癌症行胰腺切除术患者,评估90天内症状性静脉血栓事件。出院后接受延长预防者与未接受者相比,任何血栓、深静脉血栓/肺栓塞、肠系膜静脉血栓或临床显著出血发生率均无差异;出院后预防者中体重指数升高与静脉血栓事件风险增加独立相关。
要点
- 胰腺癌切除术后常规药物预防未降低深静脉血栓、肺栓塞或肠系膜静脉血栓发生率。
- 出院后延长预防患者中,体重指数升高是静脉血栓事件的显著危险因素。
- 现有预防策略可能不足,未来或需采用基于体重的剂量方案。
核心结论
- 胰腺癌切除术后常规药物预防未减少深静脉血栓、肺栓塞或肠系膜静脉血栓发生率。
- 出院时接受延长预防的患者中,体重指数升高与出院后静脉血栓事件风险增加相关。
- 提示当前预防策略可能不充分,未来策略或可采用基于体重的给药方案。
研究设计与样本
- 单中心回顾性综述,纳入2013至2024年间因癌症行胰腺切除术的患者共1667例。
- 评估术后90天症状性静脉血栓事件(肺栓塞、深静脉血栓、肠系膜静脉血栓)发生率。
- 围术期变量依据美国国家手术质量改进计划和国际胰腺外科研究组定义。
- 进行单变量和多变量分析;机构延长预防实践为每日一次皮下依诺肝素28天。
主要发现
- 患者平均年龄67±10.7岁,平均体重指数27±5.8;大多数手术为胰头切除(1303例[78%])。
- 术后血栓事件发生115例(6.9%),深静脉血栓或肺栓塞63例(3.8%),肠系膜静脉血栓58例(3.5%)。
- 排除住院期间静脉血栓事件后,接受与未接受药物预防患者间任何血栓、深静脉血栓/肺栓塞、肠系膜静脉血栓或临床显著出血事件发生率均无差异。
- 出院时接受延长预防患者中,多变量logistic回归显示体重指数增加是出院后静脉血栓事件的显著危险因素(比值比1.10;95%置信区间1.05-1.15;P≤.001)。
临床怎么用
- 胰腺癌切除术后按现行28天皮下依诺肝素方案预防,未显示降低术后静脉血栓事件。
- 对出院时接受延长预防的患者,应关注体重指数升高带来的残余血栓风险。
- 未来可考虑基于体重的预防剂量策略,但需进一步研究验证。
局限性
- 单中心回顾性设计可能引入选择偏倚和混杂。
- 仅评估症状性静脉血栓事件,可能低估无症状事件。
- 预防组与非预防组比较非随机,存在适应证混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Twenty-eight days of extended chemoprophylaxis is recommended for patients undergoing pancreatectomy for malignancy. We hypothesized that the current strategy of extended venous thrombotic event chemoprophylaxis is ineffective in reducing postoperative venous thrombotic events. METHODS: This was a single-institution retrospective review of pancreatectomy patients with cancer. Symptomatic postoperative venous thrombotic event (pulmonary embolism, deep vein thrombosis, and mesenteric vein thrombosis) rates at 90 days were evaluated. Perioperative variables were in accordance with National Surgical Quality Improvement Program and International Study Group for Pancreatic Surgery definitions. Univariable and multivariable analyses were performed. Institutional practice for extended venous thrombotic event prophylaxis is 28 days of once-daily subcutaneous enoxaparin. RESULTS: Between 2013 and 2024, 1,667 patients underwent pancreatectomy. The mean age was 67 ± 10.7 years, with a mean body mass index of 27 ± 5.8. Most operations were pancreatic head resections (1,303 [78%]). The incidence of postoperative thrombotic events was 115 (6.9%), deep vein thrombosis or pulmonary embolism was 63 (3.8%), and mesenteric vein thrombosis (portal vein/superior mesenteric vein/splenic vein) was 58 (3.5%). Sixty-nine (60%) were diagnosed with venous thrombotic event after discharge. Excluding inpatient venous thrombotic events, comparing venous thrombotic event rates between patients with and without chemoprophylaxis, there was no difference in rates of any thrombus, deep vein thrombosis/pulmonary embolism, mesenteric vein thrombosis, or clinically significant bleeding events. Among patients discharged with extended venous thrombotic event prophylaxis, multivariable logistic regression found increasing body mass index as a significant risk factor for venous thrombotic event after hospital discharge (odds ratio, 1.10; 95% confidence interval, 1.05-1.15; P ≤ .001). CONCLUSION: Routine chemoprophylaxis after pancreatectomy for cancer did not reduce rates of deep vein thrombosis, pulmonary embolism, or mesenteric vein thrombosis. Among patients discharged on extended prophylaxis, a higher body mass index was associated with an increased venous thrombotic event risk. This suggests that current prophylaxis strategies may be inadequate, and future strategies may utilize weight-based dosing for prophylaxis regimens.
引用
- Thyen AJ, Hughes AJ, Ceppa EP, et al. Extended venous thromboembolism chemoprophylaxis after pancreas surgery for cancer: Does the subcutaneous needle move the needle? Surgery. 2026. PMID: 42800756. doi:10.1016/j.surg.2026.110624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。